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Objective: To investigate the association between urinary biomarker Coll2-1NO2 (uColl2-1NO2) and
incident knee OA after 2.5 years follow-up in middle-aged overweight and obese women at high risk for
knee osteoarthritis (OA).
Design: Data were used from PROOF, a randomized controlled trial with 2.5 years follow-up evaluating
the preventive effects of a diet and exercise program and oral glucosamine sulphate (double blind and
placebo controlled), on development of incident knee OA in women with body mass index  27 kg/m2
without signs of knee OA at baseline. Baseline and 2.5 years uColl2-1NO2 concentrations were assessed
with enzyme-linked immunosorbent assay (ELISA). Primary outcome measure was incidence of knee OA
in one or both knees, deﬁned as incidence of either Kellgren & Lawrence grade 2, joint space narrowing
of 1.0 mm or knee OA according to the combined clinical and radiographic ACR-criteria. We used binary
logistic regression for the association analyses.
Results: 254 women were available for analyses. At 2.5 years follow-up, incident knee OA was present in
72 of 254 women (28.3%). An inversed association was found between baseline uColl2-1NO2 and incident
knee OA at 2.5 years (OR 0.74, 95% CI 0.55e0.99). The concentration at 2.5 years and the change in
concentration over 2.5 years did not show signiﬁcant associations with the outcome.
Conclusions: In overweight and obese middle-aged women, not higher but lower baseline uColl2-1NO2
concentration was signiﬁcantly associated with an increased risk for incident knee OA. This interesting
but counterintuitive outcome makes further validation of this biomarker warranted.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: Landsmeer M.L.A., Erasmus
PO Box 2040, 3000 CA Rot-
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Up to now there is no curative treatment for knee osteoarthritis
(OA), only symptomatic treatment for pain and loss of function
exists1. In this context it may be sensible to increase the focus on
prevention of the initial development of knee OA2. In order to
progress in this area we need to detect knee OA in an earlier, pre-
clinical and preradiographic phase.
Currently, no sufﬁcient tools for this aim exist. Plain knee radi-
ography for measuring joint space width has a relatively large
precision error and low sensitivity3. Magnetic resonance imaging
(MRI) is more sensitive in detecting features of knee OA4, but is nottd. All rights reserved.
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availability1. Given the limitations of imaging biomarkers for pre-
clinical or preradiographic knee OA, biochemical markers are
investigated as alternatives5. One of these, the Coll2-1NO2 peptide,
represents the combination of collagen type II degradation prod-
ucts (Coll2-1) and reactive nitrogen and oxygen species (RNOS), NO
and O2, and can be measured systemically in urine or serum6.
Elevated production of RNOS has been observed in chronic in-
ﬂammatory conditions, including established OA, but the effect of
the preclinical and preradiographic phase of OA is still unknown7.
As a low grade chronic inﬂammation has been suggested to be
involved in the development of OA, before visible cartilage
degeneration has occurred8, we might hypothesize that elevated
RNOS levels and thus elevated Coll2-1NO2 concentrations could be
measured in the pre-OA phase as well.
The aim of this study is therefore to explore the potency of
Coll2-1NO2 in detecting disease activity in preclinical and pre-
radiographic knee OA, as earlier diagnosis of disease activity en-
ables development of preventive therapies. We explored whether
the baseline uColl2-1NO2 concentration in subjects at risk for
developing knee OAwas associated with incident knee OA 2.5 years
later. Additionally, we explored whether the concentration at 2.5
years was cross-sectionally associated and whether the change in
concentration over 2.5 years was associated with incident knee OA.
Method
Study design, setting, and population
We used data from the PROOF study (Prevention of knee Oste-
oarthritis in Overweight Females, ISRCTN 42823086)9. The PROOF
study is a randomized controlled trial, with a 22 factorial design
and 2.5 years follow-up, which evaluates the preventive effects of a
diet and exercise program (DEP) and of oral glucosamine sulphate,
double blind and placebo controlled (GSvP), on the development of
knee OA in overweight and obese middle-aged women. Inclusion
criteria were age 50e60 years and BMI 27 kg/m2, as those are
proven risk factors for knee OA10,11. All participants were recruited
by their General Practitioner (GP) and had to be free of knee OA
according to the clinical and radiographic criteria of the American
College of Rheumatology (ACR)12. The participants had to master
the Dutch language and had to be free of major co-morbidities, free
of inﬂammatory rheumatic diseases, not under treatment of a
physical therapist or GP for knee complaints, not using walking aids
and not using oral glucosamine for the last 6 months. We treated
data from PROOF as a pre-clinical OA cohort by adjusting analyses
for the randomization groups. The Medical Ethics committee of
Erasmus MC University Medical Center Rotterdam approved the
PROOF study and all the participants gave written informed
consent.
Radiography
Posterior-anterior radiographs of both knees were taken at
baseline and at 2.5 years, using the semi-ﬂexed MTP view13. A
trained researcher blinded for clinical outcomes (MR) scored all
radiographs, baseline and follow-up at once with known sequence
using the Kellgren & Lawrence (K&L) criteria14. A random subset of
20% of the radiographs was independently scored by a second
researcher (JR) blinded for clinical outcomes. The Cohen's kappa
measure of agreement was moderate with a value of 0.6. Minimal
joint space width was measured digitally in each tibiofemoral
compartment, according to the method of Lequesne15, using the
average independent score of two researchers (JR and BdV), blinded
for the clinical outcomes. Scores with a difference 2.0 mmbetween the researchers were re-evaluated in a consensus
meeting. The inter-observer agreement for medial and lateral joint
space narrowing was substantial with kappa values of 0.67 and
0.76, respectively. Medial anatomical knee alignment angle was
assessed on knee radiographs as described previously16. Normal
alignment was deﬁned as angles between 182 and 184, valgus
and varus alignment were deﬁned as angles >184 and <182
respectively17. The test for reproducibility showed good agreement
for alignment with kappa of 0.716.
Assessment of Coll2-1NO2
uColl2-1NO2 was determined at baseline and at 2.5 years in
non-fasted, second morning void urine samples. The assessment in
urine was based upon the qualiﬁcation of the biomarker according
to the BIPED classiﬁcation: Coll2-1NO2 in urine is qualiﬁed as
biomarker of prognosis18. A detailed description of the identiﬁca-
tion of Coll2-1NO2 can be found in previous publications18,19. In
short, uColl2-1NO2 concentration was assessed by enzyme-linked
immunosorbent assay (ELISA) based on the method described by
Rosenquist et al.20 using a polyclonal antibody against antigenic
determinants of uColl2-1NO2 according to the instructions of the
manufacturer (Artialis s.a, Liege, Belgium). 150 ml of urine was
needed for each sample. After thawing, total assay time was within
a maximum of 3 h. The precision of the immunoassay of Coll2-
1NO2 in urine was previously established by Deberg et al.18 and
demonstrated an intra-assay coefﬁcient of variation (CV) of 8.3%
and an inter-assay CV of 13.6%. In our study, uColl2-1NO2 was
measured in triplicate and two additional urine samples were
added on each plate as control. The inter-assay CVs for these two
controls were respectively 9.6% and 11%.
uColl2-1NO2 concentration was adjusted for urinary creatinine
concentrations by expressing the results as nmol/mmol (nM/mM)
creatinine. The creatinine was measured by the method of Jaffe21
with the MicroVue Creatinine Assay Kit (Quidel, San Diego USA)
on a MEGA autoanalyzer (Merck, Germany).
Questionnaires, physical examination and blood samples
At baseline all subjects ﬁlled in a questionnaire to record de-
mographic (age, BMI, postmenopausal status, ethnicity) and clinical
characteristics including questions on injury, physical activity
(measured with the Short QUestionnaire to ASsess Health-
enhancing physical activity (SQUASH)22), knee complaints (“did
you experience knee pain in the past 12 months?”) and ‘self-re-
ported’ OA in other joints. Body weight, body height, blood pres-
sure, abdominal circumference, skin folds and Heberden's nodes on
both hands were assessed at the research center. Non-fasted HbA1c
concentration (mmol/mol) and total cholesterol concentration
(mmol/L) were determined from blood samples taken at baseline.
Outcome
The primary outcome measure of this study was incidence of
knee OA in one or both knees at 2.5 years. Incidence of knee OAwas
deﬁned as either K&L grade  2, joint space narrowing (JSN) of
1.0 mm23 or knee OA according to the combined clinical and
radiographic ACR criteria (ACR knee OA). Secondary outcome
measures were the separate clinical and radiographic deﬁnitions of
the primary outcome.
Statistical analysis
For the present study, participants with available baseline and
2.5 years uColl2-1NO2 concentrations and with a complete follow-
Table I
Mean (±SD) or median (IQR) of baseline variables
N-subjects 254
General
Age (yr) 55.8 ± 3.19
Ethnicity
Western 95.7%
Other 3.1%
Postmenopausal status 69.7%
Years postmenopausal 7.6 ± 5.3
Metabolic
BMI (kg/m2) 31.9 ± 3.97
Weight (kg) 87.3 ± 12.7
Physical activity score (SQUASH)* 7058.3 ± 3672.4
Joint speciﬁc
Heberden's nodes 27.2%
WOMAC (0e100)**
Pain 6.2 ± 10.13
Function 6.2 ± 10.13
Stiffness 11.4 ± 17.0
K&L
Grade 0 bilateral 45.3%
Grade 1 unilateral 22.4%
Grade 1 bilateral 32.3%
Minimal JSW***
Medial (mm) 4.9 ± 0.7
Lateral (mm) 6.1 ± 0.9
Varus alignment
Unilateral 17.7%
Bilateral 26.8%
Mild symptoms
Unilateral 25.6%
Bilateral 17.3%
History of knee injury
Unilateral 17.7%
Bilateral 2.8%
Biomarker
Mean uColl2-1NO2/creatinine (nM/mM) 0.0330 ± 0.0165
Median uColl2-1NO2/creatinine (nM/mM) 0.0313 (IQR 0.0220e0.0406)
SD¼ standard deviation. IQR¼ interquartile range. * Higher scores represent higher
physical activity. ** Higher scores represent more pain/stiffness/worse function. ***
JSW: joint space width.
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described as percentages for categorical/dichotomous data and as
means ± standard deviation (SD) or medians (interquartile range,
IQR) for continuous data.
For exploratory analyses, we conducted paired and
independent-samples Student's t-tests with untransformed uColl2-
1NO2 data; The paired t-test to evaluate the difference between
mean uColl2-1NO2 at baseline and 2.5 years within the incident
and non-incident knee OA women; The independent-samples t-
tests to compare baseline-, 2.5 years- and change over 2.5 years-
concentrations between the women with and without incident
knee OA.
For the regression analyses of uColl2-1NO2 with primary and
secondary outcomes, uColl2-1NO2 was logarithmically trans-
formed to obtain normally distributed residuals. First, possible
confounding variables and prognostic factors in the association of
uColl2-1NO2 with the primary and secondary outcomes were
determined by univariable linear regression analyses. The selection
of the different demographic, metabolic, functional and radio-
graphic variables was based on their possible relation with uColl2-
1NO2 and knee OA10,19,24. Variables with a univariable P-value <0.2
and with an r-value <0.7 (cut-off point for multicollinearity) were
adopted in a multivariable regression analysis (using the Enter
method) to analyse signiﬁcant associations with uColl2-1NO2.
Subsequently, we analysed the association of uColl2-1NO2 with
the primary and secondary outcome measures. First, we deter-
mined the association of baseline uColl2-1NO2 through binary lo-
gistic regression, using 3 different models. The ﬁrst model was
unadjusted, the second model was adjusted for age and BMI, as
these are established risk factors for knee OA. The fully adjusted
model 3 was adjusted for age, BMI, randomization groups (DEP,
GSvP and their multiplicative interaction), possible confounders
and prognostic factors from the multivariable analysis and for K&L
grade at baseline (0 vs 1), as this has already been shown to be a
prognostic factor for incident knee OA in the PROOF study9. Next,
we analysed the cross-sectional associations of uColl2-1NO2 with
prevalent knee OA and secondary outcomes at 2.5 years to evaluate
the diagnostic value of uColl2-1NO2. Finally, we analysed the as-
sociation of the change in uColl2-1NO2 concentration over 2.5
years, corrected for baseline concentration, with the primary and
secondary outcomes. All analyses were performed with the three
models.
To facilitate interpretation of the regression associations,
uColl2-1NO2 was standardized into z-scores. Results for the
regression analyses were presented as odds ratios per standard
deviation (SD) increase in log uColl2-1NO2 and their corresponding
95% conﬁdence intervals. Statistical analyses were performed with
SPSS 20.0 (Chicago, IL). A P-value < 0.05 was deﬁned as statistically
signiﬁcant.
Results
Characteristics of the study population
254 of 407 womenwith mean age of 55.8 years ± 3.19 and mean
BMI of 31.0 kg/m2 ± 3.97 were available for current analyses. The
reasons for missing data were as follows: 1) unwilling to continue
participation (28/407), 2) unattainable during follow-up (12/407),
3) no urine to the lab (8/407) 4) sample below the limit of detection
of the test (61/407), 5) excluded based on K&L  2 at baseline (42/
407) and 6) deceased during follow-up (2/407). Analysis of the
baseline differences between missing and non-missing subjects
showed a statistically signiﬁcant higher fat percentage (44.4% vs
43.0%), lower cholesterol concentration (5.9 mmol/L vs 6.1 mmol/L)
and a higher percentage of varus alignment (55.7% vs 44.8%) inthose missing. These differences did not seem to be relevant, as no
correlation of these variables with Coll2-1NO2 was found. Distri-
bution, means and/or medians of baseline characteristics are dis-
played in Table I.
Incident knee OA according to the primary outcome was found
in 72/254 women (28.3%). Medial JSN was found in 27/254 (10.6%),
lateral JSN in 26/254 (10.2%), ACR deﬁned knee OA in 20/254 (7.9%)
and K&L grade  2 in 23/254 women (9.1%).Exploratory associations between uColl2-1NO2 and incident knee
OA
Mean uColl2-1NO2 concentration for the total study group was
0.033 nM/mM creatinine ± 0.017 at baseline and 0.034 nM/
mM±0.017 at 2.5 years. Themean creatinine value of all sampleswas
7.69 mM/L ± 4.36. Mean baseline uColl2-1NO2 concentration was
signiﬁcantly lower in the women with incident knee OA as primary
outcome after 2.5 years compared to the women without incident
knee OA (0.029 nM/mM ± 0.013 vs 0.034 nM/mM ± 0.017, P ¼ 0.03).
The concentration at 2.5 years showed no signiﬁcant difference be-
tween the women with and without incident knee OA (0.034 nM/
mM ± 0.018 vs 0.034 nM/mM ± 0.017, P ¼ 0.76). The change from
baseline over 2.5 years within both groups was not signiﬁcant.
However, the change between both groups over 2.5 years was sig-
niﬁcant. Themean increase in thewomenwith incident knee OAwas
0.005 nM/mM ± 0.021 vs a mean decrease of 0.001 nM/mM ± 0.020
in the women without incident knee OA (P ¼ 0.04), see Fig. 1.
Fig. 1. uColl2-1NO2 (nM/mM) levels at baseline and 2.5 years follow-up for womenwithout and with incident knee OA at 2.5 years, not adjusted for BMI, age, K&L grade (0 vs 1) and
randomization groups. P-values obtained from paired t-tests, to evaluate the difference between mean uColl2-1NO2 at baseline and 2.5 years within the incident and non-incident
knee OA women. P-value* is obtained from independent t-test, to compare the change over 2.5 years in the women with and without incident knee OA. P-value** is obtained from
independent t-test, to compare the baseline difference in women with and without incident knee OA. BL ¼ Baseline, FU ¼ Follow-up.
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The variables ethnicity (Caucasian), weight, Heberden's nodes,
SQUASH score and ‘self-reported’ OA in other joints were positively
associated with uColl2-1NO2. Age and years since menopause were
negatively associated with uColl2-1NO2. The variables BMI, waist
circumference, fat percentage, total cholesterol, HbA1c, K&L grade
0 vs 1, knee alignment, mild knee symptoms and history of knee
injury were not univariable associated with uColl2-1NO2. In the
multivariable regression analyses, none of the variables were
signiﬁcantly associated with uColl2-1NO2.
The associations of baseline uColl2-1NO2 with primary and
secondary outcomes are displayed in Table II, showing a signiﬁcant
inversed association between baseline uColl2-1NO2 and incident
knee OA at 2.5 years, both in adjusted model 2 and 3 (OR 0.74, 95%
CI 0.55e0.99 inmodel 3). No signiﬁcant associations were found for
the secondary outcomes.Associations of uColl2-1NO2 at 2.5 years and prevalent knee OA
The uColl2-1NO2 concentration at 2.5 years did not show a
signiﬁcant cross-sectional association with prevalent knee OA (OR
1.03, 95% CI 0.77e1.37 in model 3) or with the separate outcome
deﬁnitions, in any of the models (medial JSN: OR 0.93, 95% CI0.63e1.38, lateral JSN: OR 0.88, 95% CI 0.57e1.34, ACR knee OA: OR
1.39, 95% CI 0.82e2.37, and K&L2: OR 0.92, 95% CI 0.57e1.47, all in
model 3).
Change of uColl2-1NO2 and incident knee OA
No signiﬁcant association was found between the change in
concentration over 2.5 years and incident knee OA (OR 1.10, 95% CI
0.81e1.48 in model 3), nor for the association with the separate
outcome deﬁnitions, in any of the models (medial JSN: OR 0.94, 95%
CI 0.62e1.41, lateral JSN: OR 0.88, 95% CI 0.57e1.36, ACR knee OA:
OR 1.55, 95% CI 0.88e2.72, and K&L 2: OR 0.97, 95% CI 0.60e1.57,
all in model 3).
Discussion
This is the ﬁrst study that assessed the uColl2-1NO2 biomarker
in a high-risk pre-OA cohort of middle-aged overweight and obese
women.We found that a lower baseline uColl2-1NO2 concentration
was signiﬁcantly associated with an increased risk of incident knee
OA after 2.5 years. The cross-sectional association between uColl2-
1NO2 at 2.5 years and prevalent knee OA and the association be-
tween the change of uColl2-1NO2 and incident knee OA were not
statistically signiﬁcant.
Table II
Multivariable adjusted association between uColl2-1NO2 and adjusted variables age, BMI and K&L grade (0 vs 1) at baseline and overall incident knee OA and separate
incidence deﬁnitions at 2.5 years
Cases (%) uColl2-1NO2 Age BMI K&L (0 vs 1)
Or 95% CI Or 95% CI Or 95% CI Or 95% CI
Incident knee OA* 72/254(28.3) Model 1z 0.77 0.58e1.02 e e e
Model 2x 0.74 0.56e0.99 1.03 0.94e1.22 1.10 1.03e1.18 e
Model 3k 0.74 0.55e0.99 1.02 0.94e1.12 1.09 1.01e1.17 1.77 0.98e3.20
Medial JSNy 27/254 (10.6) Model 1z 0.99 0.65e1.49 e e e
Model 2x 0.83 0.63e1.46 0.99 0.87e1.13 1.08 0.98e1.18 e
Model 3k 1.00 0.61e1.49 1.00 0.88e1.13 1.06 0.96e1.16 1.37 0.58e3.23
Lateral JSNy 26/254 (10.2) Model 1z 0.95 0.63e1.44 e e e
Model 2x 0.94 0.62e1.43 1.02 0.89e1.16 1.05 0.95e1.16 e
Model 3k 0.95 0.63e1.43 1.02 0.89e1.17 1.10 0.99e1.22 0.38 0.16e0.93
ACR criteriay 20/254(7.9) Model 1z 0.77 0.51e1.18 e e e
Model 2x 0.72 0.47e1.12 0.96 0.83e1.12 1.11 1.00e1.23 e
Model 3k 0.70 0.43e1.12 0.96 0.83e1.12 1.07 0.97e1.19 7.87 1.74e35.55
K&L  2y 23/254 (9.1) Model 1z 0.83 0.55e1.25 e e e
Model 2x 0.78 0.50e1.20 1.08 0.93e1.25 1.18 1.08e1.30 e
Model 3k 0.74 0.47e1.18 1.07 0.93e1.24 1.15 1.04e1.26 3.44 1.09e10.85
Bold indicates P-value <0.05.
CI ¼ conﬁdence interval. OA ¼ osteoarthritis.
* Incidence of knee OA at 2.5 years: either K&L grade 2, joint space narrowing (JSN) of 1.0 mm or knee OA according to the combined clinical and radiographic ACR
criteria.
y Secondary outcomes: separate deﬁnitions of incidence of knee OA.
z Model 1: unadjusted.
x Model 2: adjusted for age and BMI.
k Model 3: adjusted for age, BMI, randomisation groups, interaction between randomisation groups and K&L grade (0 vs 1) at baseline.
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Serum Coll2-1NO2was found to be signiﬁcantly elevated in knee
OA patients, compared to age-matched controls19. In another knee
study, the one year uColl2-1NO2 change from baseline was shown
to be predictive for radiographic medial joint space narrowing over
3 years18. Our study, unlike the others, was performedwith patients
at risk for knee OA instead of established knee OA.
Against our expectations, a lower baseline uColl2-1NO2 con-
centration was found in the women who developed incident knee
OA, compared to those who did not. In vitro studies25-27 indicate
that in the development of OA, besides catabolic inﬂammatory
processes, compensatory anti-inﬂammatory mechanisms occur in
an attempt by chondrocytes to restore cartilage homeostasis26.
In vitro studies show that anti-inﬂammatory cytokine IL-10 can
inhibit NO expression27 and can antagonize chondrocyte
apoptosis25. These studies might give some support for our,
somewhat counterintuitive ﬁnding of lower baseline uColl2-1NO2
formation. However, we can only speculate on the role of anti-
inﬂammatory mechanisms, as this had not been studied compre-
hensively so far in the context of OA28. Moreover, some studies
suggest that the anti-inﬂammatory response may never control the
inﬂammatory response in OA completely29. We do not know how
this balance is acting in the preclinical and preradiographic phase
as studied in the present study. Besides, we might also hypothesize
that subjects who develop OA have initially lower amounts of
cartilage, which reduce the overall formation of uColl2-1NO2.
We did perform our analyses on person level instead of knee
level for different reasons. First, we had the aim to analyse the
associations for women and not for knees. The biomarker was
furthermore measured systemically and not locally. Moreover, a
total of 72 women developed knee OA after 2.5 years follow-up, but
only 14 of them had bilateral knee OA. As a result, this would not
provide enough power to distinguish between uni- and bilateral
knee OA. In ordinal regression analyses (data not shown) we found
stronger, but not signiﬁcant, associations for bilateral compared to
unilateral knee OA.
In our exploratory analyses, we found a signiﬁcant difference in
change of uColl2-1NO2 concentration over 2.5 years betweenincident and non-incident knee OA. Previously, Deberg et al. sug-
gested that uColl2-1NO2 levels do not increase in preclinical and
preradiographic OA phase, but later in OA development18. This is
supported by the signiﬁcant increase of uColl2-1NO2 in women
with incident knee OA compared to the women without knee OA
development. This increase of uColl2-1NO2 over time might be
caused by the eventual failure of the above mentioned compen-
satory anti-inﬂammatory mechanisms during further development
of knee OA. However, the signiﬁcance is found only in our explor-
atory non-logarithmically transformed analyses.
In the 2.5 years cross-sectional data and in the change of uColl2-
1NO2 concentration over 2.5 years, the positive association with
ACR knee OA was most pronounced, albeit not statistically signiﬁ-
cant. The absence of signiﬁcance might be due to the small number
of women who developed ACR knee OA (20/254, 7.9%) or the
relatively short follow-up period of 2.5 years. The relation between
(chronic) inﬂammation and knee pain30,31 and between (chronic)
inﬂammation and osteophytes32 as described in literature, seems to
be reﬂected by this ﬁnding of a positive trend for the association
between uColl2-1NO2 (inﬂammatory marker) and ACR knee OA
(pain and osteophytes).
Strengths and limitations
The major strength of this study is its focus on preclinical and
preradiographic knee OA. Especially in high risk subjects there is a
need for tools that could help detecting disease activity in this
phase of knee OA. The assessment of the potency of the uColl2-
1NO2 biomarker in this study is contributing to fulﬁl this need.
We are aware of the relatively high number of analyses per-
formed, resulting in an increased risk of a type I error. Nevertheless,
given the exploratory nature of this study, these results should be
seen as the ﬁrst step in the validation of the uColl2-1NO2 biomarker
in high-risk pre-OA women.
One of the limitations of this study is that we could not un-
doubtedly exclude the presence of OA in other joints than the knee,
which might have inﬂuenced the level of systemic uColl2-1NO2.
However, we have taken the presence of Heberden's nodes and the
self-reported OA in other joints into account in our analyses.
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over, the participants in the present study were asked to identify
the location of their OA from a list of ﬁve (hip, ankle, hand, back/
neck, other), which is known to improve the accuracy of self-
reporting35. In this way we intended to correct as precisely as
possible, making the results applicable to the knee joints.
Conclusions and implications
In this study of overweight and obese middle-aged women at
risk for developing knee OA, lower baseline uColl2-1NO2 levels
were signiﬁcantly associated with increased risk of overall inci-
dence of knee OA 2.5 years later. These results might be caused by
compensatory mechanisms in the preclinical and preradiographic
phase of the pathophysiologic process, by lower NO production or
by an overall lower cartilage volume in people developing knee OA.
In the preclinical and preradiographic phase, distinguishing
subjects who are at risk to develop deﬁnite knee OA from those
who are not, has a high priority. It seems important to further
validate the Coll2-1NO2 biomarker and to increase our under-
standing of this very early phase of knee OA to enable development
of preventive therapies for those subjects prone to develop knee
OA.
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